RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
29,11 US$
arrow_upward
+1,22%(+0,35) 1K
29,11 US$
0,00% (0,00)
bedtimeYopilgandan keyin
Savdolar yopilgan: 24-iyn, 16:00:01 (GMT-4) · USD
search
Barcha belgilar
1K
5K
1O
6O
YBB
1Y
5Y
MAKS
| Belgi | Narxi | Oʻzgartirishlar | Dinamika (%) |
|---|
insights_autoRARE tikeri uchun statistika yaratilmoqda...
Ochish
29,02 US$
Yuqori
30,14 US$
Past
29,01 US$
Bozor kapitali
2,87 mlrd
Oʻrtacha hajm
1,75 mln
Hajmi
16,00
52 haftalik eng yuqori
42,37 US$
52 haftalik eng past
18,29 US$
Aksiya boʻyicha daromad
-6,10 US$
Beta
0,37
Muomaladagi aksiyalar
98,49 mln
Xodimlar soni
1 ming
Ochish
29,02 US$
Yuqori
30,14 US$
Past
29,01 US$
Bozor kapitali
2,87 mlrd
Oʻrtacha hajm
1,75 mln
Hajmi
16,00
52 haftalik eng yuqori
42,37 US$
52 haftalik eng past
18,29 US$
Aksiya boʻyicha daromad
-6,10 US$
Beta
0,37
Muomaladagi aksiyalar
98,49 mln
Xodimlar soni
1 ming
Yangiliklar
Internetdagi manbalardan
Simply Wall Street
·
7 daqiqa oldin
Xcel Energy (XEL) Is Up 5.2% After Regulators Approve Major Rate Hikes And ROE Increases
Stocktwits
·
29 daqiqa oldin
ADTX Stock Loses Nasdaq Listing After Seven Reverse Splits Fail To Restore Compliance: Why Is Retail Still Bullish?
Barron's
·
22 daqiqa oldin
SK Hynix Stock Gets a Huge Double Boost Ahead of Nasdaq Listing
Seeking Alpha
·
2 soat oldin
Reiterating Our 3 Rate Cut Forecast (SPX)
Profil
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Ultragenyx Pharmaceutical Inc haqida
CEOEmil Kakkis
Xodimlar soni1,37 ming
Asos solingan2010
Bosh ofislarNovato, Kaliforniya, Amerika Qo‘shma Shtatlari
Sektor-
Veb-saytultragenyx.com
AI kontentda xatolar boʻlishi mumkin. Batafsil